vs
帕可Bio（PACB）与Prenetics Global Ltd（PRE）财务数据对比。点击上方公司名可切换其他公司
帕可Bio的季度营收约是Prenetics Global Ltd的10.4倍（$44.6M vs $4.3M）
太平洋生物科学（加利福尼亚）公司是2004年成立的美国生物技术企业，专注于研发生产基因测序相关设备，还可实现新型实时生物观测。公司拥有两大核心测序平台：基于零模波导特性的单分子实时测序平台（SMRT），以及采用天然核苷酸、无损伤掺入完成DNA结合与延伸的结合测序技术（SBB）平台。
Prenetics是一家总部位于中国香港的健康科学企业，业务辐射美国地区，专注于癌症等疾病的早期筛查、预防与干预诊疗，致力于帮助人们更早发现健康风险，助力提升相关疾病的治疗效果，推动肿瘤等重疾的早防早治，守护公众健康。
PACB vs PRE — 直观对比
营收规模更大
PACB
是对方的10.4倍
$4.3M
损益表 — Q4 2025 vs Q3 2023
| 指标 | | |
|---|---|---|
| 营收 | $44.6M | $4.3M |
| 净利润 | $-40.4M | — |
| 毛利率 | 37.1% | 44.9% |
| 营业利润率 | -92.3% | -396.2% |
| 净利率 | -90.4% | — |
| 营收同比 | 13.8% | — |
| 净利润同比 | -1802.7% | — |
| 每股收益（稀释后） | $-0.11 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PACBPRE
| Q4 25 | $44.6M | — | ||
| Q3 25 | $38.4M | — | ||
| Q2 25 | $39.8M | — | ||
| Q1 25 | $37.2M | — | ||
| Q4 24 | $39.2M | — | ||
| Q3 24 | $40.0M | — | ||
| Q2 24 | $36.0M | — | ||
| Q1 24 | $38.8M | — |
净利润PACBPRE
| Q4 25 | $-40.4M | — | ||
| Q3 25 | $-38.0M | — | ||
| Q2 25 | $-41.9M | — | ||
| Q1 25 | $-426.1M | — | ||
| Q4 24 | $2.4M | — | ||
| Q3 24 | $-60.7M | — | ||
| Q2 24 | $-173.3M | — | ||
| Q1 24 | $-78.2M | — |
毛利率PACBPRE
| Q4 25 | 37.1% | — | ||
| Q3 25 | 41.4% | — | ||
| Q2 25 | 36.9% | — | ||
| Q1 25 | -3.7% | — | ||
| Q4 24 | 25.6% | — | ||
| Q3 24 | 25.0% | — | ||
| Q2 24 | 16.5% | — | ||
| Q1 24 | 29.1% | — |
营业利润率PACBPRE
| Q4 25 | -92.3% | — | ||
| Q3 25 | -101.1% | — | ||
| Q2 25 | -112.8% | — | ||
| Q1 25 | -1154.5% | — | ||
| Q4 24 | -390.1% | — | ||
| Q3 24 | -160.3% | — | ||
| Q2 24 | -488.3% | — | ||
| Q1 24 | -209.6% | — |
净利率PACBPRE
| Q4 25 | -90.4% | — | ||
| Q3 25 | -98.9% | — | ||
| Q2 25 | -105.4% | — | ||
| Q1 25 | -1146.8% | — | ||
| Q4 24 | 6.0% | — | ||
| Q3 24 | -151.9% | — | ||
| Q2 24 | -481.3% | — | ||
| Q1 24 | -201.4% | — |
每股收益（稀释后）PACBPRE
| Q4 25 | $-0.11 | — | ||
| Q3 25 | $-0.13 | — | ||
| Q2 25 | $-0.14 | — | ||
| Q1 25 | $-1.44 | — | ||
| Q4 24 | $-0.44 | — | ||
| Q3 24 | $-0.22 | — | ||
| Q2 24 | $-0.64 | — | ||
| Q1 24 | $-0.29 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $279.5M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $5.3M | — |
| 总资产 | $784.1M | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PACBPRE
| Q4 25 | $279.5M | — | ||
| Q3 25 | $298.7M | — | ||
| Q2 25 | $314.7M | — | ||
| Q1 25 | $343.1M | — | ||
| Q4 24 | $389.9M | — | ||
| Q3 24 | $471.1M | — | ||
| Q2 24 | $509.8M | — | ||
| Q1 24 | $561.9M | — |
股东权益PACBPRE
| Q4 25 | $5.3M | — | ||
| Q3 25 | $36.1M | — | ||
| Q2 25 | $61.5M | — | ||
| Q1 25 | $91.6M | — | ||
| Q4 24 | $506.6M | — | ||
| Q3 24 | $453.1M | — | ||
| Q2 24 | $492.7M | — | ||
| Q1 24 | $649.0M | — |
总资产PACBPRE
| Q4 25 | $784.1M | — | ||
| Q3 25 | $803.2M | — | ||
| Q2 25 | $825.5M | — | ||
| Q1 25 | $860.8M | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.7B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-19.1M | — |
| 自由现金流经营现金流 - 资本支出 | $-19.9M | — |
| 自由现金流率自由现金流/营收 | -44.6% | — |
| 资本支出强度资本支出/营收 | 1.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-114.1M | — |
8季度趋势，按日历期对齐
经营现金流PACBPRE
| Q4 25 | $-19.1M | — | ||
| Q3 25 | $-18.7M | — | ||
| Q2 25 | $-29.4M | — | ||
| Q1 25 | $-44.1M | — | ||
| Q4 24 | $-30.6M | — | ||
| Q3 24 | $-45.5M | — | ||
| Q2 24 | $-54.3M | — | ||
| Q1 24 | $-75.7M | — |
自由现金流PACBPRE
| Q4 25 | $-19.9M | — | ||
| Q3 25 | $-18.8M | — | ||
| Q2 25 | $-29.9M | — | ||
| Q1 25 | $-45.4M | — | ||
| Q4 24 | $-32.3M | — | ||
| Q3 24 | $-46.3M | — | ||
| Q2 24 | $-55.7M | — | ||
| Q1 24 | $-79.6M | — |
自由现金流率PACBPRE
| Q4 25 | -44.6% | — | ||
| Q3 25 | -48.9% | — | ||
| Q2 25 | -75.3% | — | ||
| Q1 25 | -122.3% | — | ||
| Q4 24 | -82.3% | — | ||
| Q3 24 | -115.7% | — | ||
| Q2 24 | -154.8% | — | ||
| Q1 24 | -205.0% | — |
资本支出强度PACBPRE
| Q4 25 | 1.9% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 1.4% | — | ||
| Q1 25 | 3.7% | — | ||
| Q4 24 | 4.1% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 4.1% | — | ||
| Q1 24 | 10.0% | — |
现金转化率PACBPRE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -12.93× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PACB
| Products | $39.0M | 87% |
| Service And Other | $5.7M | 13% |
PRE
暂无分部数据
